Future Fertility welcomes new advisory board members heading into 2024

Future Fertility, the pioneer of AI-powered oocyte assessment, has proudly announced the expansion of its advisory board.

This distinguished group is comprised of professionals at the forefront of reproductive medicine, artificial intelligence and global healthcare. The advisory board’s members bring a wealth of expertise that spans clinical practice, embryology, scientific research, commercial strategy and AI integration.

Future Fertility held its inaugural advisory board meeting at this year’s ASRM congress in New Orleans, bringing the group together to reflect on the company’s progress in 2023 and identify areas for growth and support into 2024 and beyond.

“As a technology company that serves such a specialised area of medicine and laboratory practice, having the means to gain practical feedback, guidance and advice from industry experts will ensure our products continue to evolve in a way that meets the needs of our clients, and ultimately patients, worldwide,” says Christy Prada, CEO of Future Fertility.

“We are lucky to have such an inspiring group of leaders in their field supporting our ambitions.”

New members of Future Fertility’s advisory board include:

Sebastian Bohl – VP, Global Head of Product Planning & Portfolio Expansion, GBF Fertility at Merck Healthcare

Sebastian Bohl is an accomplished entrepreneurial leader with a diverse background that spans the pharmaceutical, diagnostics and medical devices sectors. His global and in-country roles have honed expertise in commercial strategy, marketing, consulting, and business development. With a keen drive for innovation and efficiency, he consistently delivers high performance, exemplifying a commitment to refining business models and organisational structures for optimal results. Mr Bohl’s commercial expertise aligns with Future Fertility‘s ambitions for growth in 2024.

Dr Kate Devine – Medical Director and Chief Research Officer, US Fertility

Dr Kate Devine is US Fertility’s Medical Director and Chief Research Officer. As a board-certified REI (Reproductive Endocrinologist and Infertility Specialist), she treats patients in Washington DC and was Shady Grove’s Research Director for over a decade. In her role as CRO at US Fertility, she leads a dedicated research division, expanding medical care in the field while also overseeing a culture of medical excellence at the network of clinics.  She has authored more than 40 peer-reviewed articles and has a special focus on endometrial receptivity and optimization of frozen transfer cycles.

Dr Kathy Miller – Chief Scientific Officer, Innovation Fertility

Dr Kathy Miller, with a deep background of combined experience in research and laboratory management, serves as the Chief Scientific Officer at Innovation Fertility and is also the Vice President of MedTech For Solutions. She has authored over 100 abstracts, papers, and chapters on her research, which focuses on advancements in blastocyst culture, pre-implantation genetics and other new technologies such as time-lapse and artificial intelligence. This focus makes her a valuable contributor to Future Fertility’s pursuit of innovation.

Dr Mitch Rosen – Fertility Physician and Director, UCSF Fertility Preservation Program

Based at the UCSF Center for Reproductive Health, Dr Mitch Rosen is an expert in reproductive endocrinology and fertility, uniquely holding multiple clinical and laboratory roles. He is a fertility physician and high complexity lab director (HCLD), as well as an Associate Professor at UCSF where he teaches medical students, residents, and fellows. His commitment to medical education and research enhances the clinical and scientific depth of Future Fertility’s advisory team.

Dr Prati Sharma – Reproductive Endocrinologist, CReATe

Dr Prati Sharma, a distinguished REI at CReATe in Toronto, brings a patient-centric approach to the advisory board. Active in various medical associations across North America, her extensive training and board certifications underscore her commitment to providing exceptional patient care. Dr Sharma combines her love for research in Reproductive Endocrinology and Infertility with “patient-centred” clinical practice.

These new advisory board members join the following established members:

Dr Angie Beltsos – CEO Clinical and Medical Director, Kindbody

Dr Angie Beltsos is a board-certified REI and Chief Executive Physician of Kindbody, a national network of fertility clinics and fertility benefits provider in the US. She is also the founder and was CEO and CMO of Vios Fertility Institute – a network of fertility clinics. She has received numerous awards and is a popular speaker, both nationally and internationally, and a frequent media resource on the topic of infertility. Dr Beltsos is the executive chairperson for the Midwest Reproductive Symposium International and continues to educate and mentor REI doctors and students of all stages of education.

Dr Avi Goldfarb – Chair in Artificial Intelligence and Healthcare, Rotman School of Management, University of Toronto

Professor Goldfarb’s leadership and groundbreaking research at the intersection of AI and healthcare provides pivotal insights in shaping Future Fertility’s responsible and interpretable AI solutions.

Dr Jim Meriano – Director, Embryology Laboratory, TRIO Fertility

Dr Jim Meriano has been instrumental in shaping and advancing Future Fertility’s AI-based oocyte assessment solutions. His extensive experience as an embryologist and lab director, spanning over 30 years in the field of fertility, has significantly contributed to the company’s research and academic insights.

Dr Rita Vassena – Founder and CEO, Fecundis

Dr Rita Vassena brings more than two decades of expertise in biomedical and fertility research to Future Fertility. With a notable tenure as the Global Scientific Director at Eugin Group and two terms as an Executive Member of ESHRE, she has co-authored over 110 fertility research papers. Currently leading Fecundis, Dr Vassena’s extensive experience and leadership will enrich Future Fertility’s scientific strategy.

With this accomplished advisory board, Future Fertility looks ahead to a year of commercial growth and innovation in 2024. The diverse expertise spanning clinical, embryology, commercial strategy and research uniquely positions the company to contribute significantly to its mission of developing AI-based solutions that solve real information gaps across the fertility journey.